Company intelligence / Profile preview

curasan

Kleinostheim, Bavaria, Germanycurasano.com ↗

Ownership: Private
Employees: ~17
Development stage: Commercial

Overview

curasan has over three decades of experience developing commercialized biomaterials for dental, orthopedic, spine, trauma, and wound healing applications. Their flagship products—CERASORB®, OSBONE®, OSGIDE®, ALLOSORB®, CERACELL®—are used by surgeons globally for bone/tissue regeneration. The company’s solutions are available in several European markets with a legacy of clinical use. No specific recent clinical trial results were found.

Therapeutic areas: OtherRheumatology
Modalities: Biomaterials (synthetic and allograft)Collagen sponges/membranesBone graft substitutes
Industry: Surgical Medical Devices

Drug pipeline

2 assets

CERASORB M

Commercial

Indications: Bone regeneration

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on curasan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on curasan.

Explore the full profile